Marco Perulli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Refining diagnostic boundaries and electroclinical profiles of Lennox-Gastaut syndrome through unsupervised clustering.

Refining diagnostic boundaries and electroclinical profiles of Lennox-Gastaut syndrome through unsupervised clustering.

Journal: Epilepsia
Published: May 12, 2026

Managing Fever and Vaccination Risks in Dravet Syndrome: From Pathophysiology to Clinical Practice.

Managing Fever and Vaccination Risks in Dravet Syndrome: From Pathophysiology to Clinical Practice.

Journal: Journal of child neurology
Published: March 04, 2026

Real-world effectiveness and tolerability of highly purified cannabidiol in patients with monogenic developmental and epileptic encephalopathies with highly active epilepsy.

Real-world effectiveness and tolerability of highly purified cannabidiol in patients with monogenic developmental and epileptic encephalopathies with highly active epilepsy.

Journal: Epilepsy & behavior : E&B
Published: February 10, 2026

Epilepsy and Neurodevelopment Outcomes 24 Months after Neonatal Hypoxic-Ischemic Encephalopathy and Predictive Factors of Post-neonatal Epilepsy.

Epilepsy and Neurodevelopment Outcomes 24 Months after Neonatal Hypoxic-Ischemic Encephalopathy and Predictive Factors of Post-neonatal Epilepsy.

Journal: Neuropediatrics
Published: January 29, 2026

Beyond seizure control: Functional and caregiver-reported outcomes of long-term fenfluramine treatment in Dravet syndrome.

Beyond seizure control: Functional and caregiver-reported outcomes of long-term fenfluramine treatment in Dravet syndrome.

Journal: Epilepsy & behavior : E&B
Published: December 12, 2025

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.

Journal: Epilepsia open
Published: November 08, 2025

Real-world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2-q13.1 duplication and deletion syndromes: A multicenter study.

Real-world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2-q13.1 duplication and deletion syndromes: A multicenter study.

Journal: Epilepsia open
Published: September 08, 2025

Advancing Non-Invasive Ophthalmic Imaging in Sturge-Weber Syndrome: Clinical Guidelines Towards Early Choroidal Hemangioma Detection.

Advancing Non-Invasive Ophthalmic Imaging in Sturge-Weber Syndrome: Clinical Guidelines Towards Early Choroidal Hemangioma Detection.

Journal: Journal of clinical medicine
Published: August 22, 2025

Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.

Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.

Journal: Epilepsia
Published: June 24, 2025

Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies.

Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies.

Journal: Epilepsia open
Published: May 30, 2025

DNM1L-related rapid-onset encephalopathy with super-refractory status epilepticus: case report and literature review.

DNM1L-related rapid-onset encephalopathy with super-refractory status epilepticus: case report and literature review.

Journal: Seizure
Published: April 27, 2025

Second-Line Medications for Women Aged 10 to 50 Years With Idiopathic Generalized Epilepsy.

Second-Line Medications for Women Aged 10 to 50 Years With Idiopathic Generalized Epilepsy.

Journal: JAMA network open
Published: March 10, 2025
Showing 1-12 of 32

Last Updated: 09/26/2026